| Aug 6 |
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
| Aug 1 |
Apellis Pharmaceuticals, Inc. (APLS) Q2 2024 Earnings Call Transcript
|
| Aug 1 |
Apellis (APLS) Q2 Earnings Beat, Syfovre Sales Drive Revenues
|
| Aug 1 |
Compared to Estimates, Apellis Pharmaceuticals (APLS) Q2 Earnings: A Look at Key Metrics
|
| Aug 1 |
Apellis Pharmaceuticals, Inc. (APLS) Reports Q2 Loss, Tops Revenue Estimates
|
| Aug 1 |
Apellis Pharmaceuticals GAAP EPS of -$0.30 beats by $0.02, revenue of $199.69M beats by $8.38M
|
| Aug 1 |
Apellis Pharmaceuticals Reports Second Quarter 2024 Financial Results
|
| Jul 31 |
Apellis Pharmaceuticals Q2 2024 Earnings Preview
|
| Jul 30 |
When Will Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Breakeven?
|
| Jul 25 |
Apellis Pharmaceuticals, Inc. (APLS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
|
